Exchange: NASDAQ·Updated 04:15 PM EST
INKT logo

INKT MiNK Therapeutics Inc

$7.98
$0.59
(6.85%)
Today
Closed $8.02
$0.04
(0.50%)
After Hours
Reported EarningsNov 11
Mkt Cap$44.2M
Vol19,031.00

About INKT

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded by Garo H. Armen in 2017 and is headquartered in New York, NY.
43

Bearish Sentiment

How do you feel about INKT?

enkemm
$INKT The total treatment cost decreases dramatically when a patient avoids mechanical ventilation or only requires it for a very short duration, and the illness resolves within 7 to 14 days. Because intensive care costs are heavily tied to time spent on life support, shortening or eliminating the ventilation window removes the primary drivers of ARDS expense. An ARDS case that resolves without invasive mechanical ventilation generally mirrors the cost of a standard, uncomplicated pneumonia or acute respiratory infection hospitalization. Globally, this shifts the total cost down to a baseline range of $8,000 to $20,000, representing a 70% to 85% reduction in total resource expenditure. Thus...INKT charging 30,000 to 60,000 per patient treatment would save insurance companies hundreds of thousands of dollars in initial and follow up care. 120,000 cases a year in the US...3 million worldwide. Currently, no approved treatment. You tell me what T-797 is worth.... Pg2
6
Spartrap
$INKT -:$3M raised through ATM this Q (about 6-7% dilution) - believe they have runway for the next 12 months - topline of randomized ARDS trial in 2H 2027 Remarkably efficient use of capital but it's almost comical at this point and gives like this whole company is still some Skunk Works of AGEN. Those guys should have 90 mil to work with not 9, LOL!!
1
1
enkemm
$INKT A final benefit from the designation is designated products may qualify for priority review (shortening the FDA's final review timeline) and rolling review, which allows companies to submit sections of their marketing application as they are completed. To apply for the designation, sponsors must submit an RMAT request either alongside a new Investigational New Drug (IND) application or as an amendment to an active IND. Once the request is received, the FDA reviews the application and notifies the sponsor within 60 calendar days whether the designation is granted. If management gets a Phase III trial registered before December 31, then applies for RMAT, we could have the approval by March 1, 2027. NICE.......................................... Page 3
3
enkemm
$INKT In addition, the therapy must be intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. Finally, early clinical data must show that the therapy has the potential to address unmet medical needs for that condition. Unlike Breakthrough Therapy designation, RMAT does not require evidence proving the drug is a substantial improvement over existing treatments. The key benefits from a RMAT designation are that it provides all the benefits of the FDA's Fast Track and Breakthrough Therapy programs. Also, sponsors receive meetings with senior FDA managers to design efficient clinical trials, and developers can discuss using surrogate or intermediate endpoints to support accelerated approval, rather than waiting years for traditional long-term clinical outcomes. Additionally, there are flexible ways to satisfy post-approval study requirements, including using real-world evidence, patient registries, or electronic health records. Page 2
3
OrientBeach
$INKT Q3 10-K page 17 ‘. . . and a proposed hierarchical endpoint of survival with VV-ECMO at Day 14, followed by all-cause mortality through Day 28. We plan to meet with FDA before YE ‘26 to discuss the proposed design could contribute to a registration-enabling PIII trial, and we intend to pursue Regenerative Medicine Advanced Therapy designation’ Holy Smokes Batman
2
focafoca99
$INKT noted Q3 2026 results with first product revenue from agenT-797 and ARPA-H selection for deployable cell therapy.
2
Rayvio_News_Filter
$INKT 🏛️ MiNK Therapeutics, Inc. was selected as the cell therapy for the Draper-led team in ARPA-H's BoSS program, which provides up to $87 million in program-wide funding to advance room-temperature deployable living medicines. Timely market event
2
focafoca99
$INKT details its upcoming Q3 2026 earnings release on Nov 11 and iNKT therapy progress update.
2
OrientBeach
$INKT Update: ‘In the nine months ended September 30th, 2026 the company sold 313,478 shares in net proceeds of $4.4M. No shares were sold during the three months ended September 30, 2026’ Page 12 Q3 10-K
1
weichsel1
$INKT So this morning was really no new news. Did not include the substantive updates that we hoped for. But also no bad news.
1
OrientBeach
$INKT The company ATM raised ~$3.0M or more than double their ATM raise in Q2. Strange that the total Q3 trading volume was only 816.2K shares, and average SP at Close was $11.42/shr. This means they hit the ATM for 262,753 shares, for 1/3rd of all shares traded in Q3 were ATM sales Tutes need to report their Q3 activity by Monday … I am expecting institutions increased their holding by at least 150.0K shares … I let you know Tuesday
1
StocktwitsEarnings
$INKT Q3 '26 Earnings Results & Recap MiNK Therapeutics recognized $200K in first pre-commercial product revenue; net loss was $2.6M, or $0.50 per share, a 23% reduction in net loss per share year over year.
1
weichsel1
$INKT except explanation for the further drop today? Any news? Or just market volatility?
svertical1
$INKT Okay, but your missing $22 Million from Dr Soon-Shiong with a bottomless wallet. Not to mention ImmunityBio/INKT Trial, which should unlock billion dollar opportunity. ARDS, Pneumonia and Sepsis Trials are NOT years-long, endless Trials.

Advertisement|Remove ads.